i*x
2 楼
请教肿瘤新抗原/个性化疫苗这个领域,的转化前景怎样?
非常感谢!
非常感谢!
l*d
6 楼
我老没啥neoantigen的经验,只做过beta cell auto antigen。
感觉上neoantigen不是问题重点,一旦触发antigen specific immunity,这个antigen
就不是很重要了。在beta cell这块,先是anti-GAD 和-Insulin, 等T cell杀红眼了,
啥antigen都可以recognize。
--------------------------------------------------------------------
再上点干货:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580128/
Antigen-Based Therapy with Glutamic Acid Decarboxylase (GAD) Vaccine in
Patients with Recent-Onset Type 1 Diabetes: A Randomised Double-Masked
Controlled Trial
Findings
The ratio (experimental to control) of the adjusted population mean of C-
peptide for the GAD-alum ×3 and GAD-alum ×2/alum ×1 groups is 0.998 (95%
CI: [0.779, 1.22], p = 0.98) and 0.926 (95% CI: [0.720, 1.13], p = 0.50),
respectively. HbA1c and insulin use did not differ between groups. There was
no difference in rate or severity of adverse events between groups.
Interpretation $$$
Antigen-based immunotherapy therapy using GAD-alum given subcutaneously in
two or three doses over 4 to 12 weeks does not alter the course of loss of
insulin secretion over one year in subjects with recently diagnosed T1DM.
While antigen-based therapy is a highly desireable treatment and is
effective in animal models, translation to human autoimmune disease remains
a challenge.
感觉上neoantigen不是问题重点,一旦触发antigen specific immunity,这个antigen
就不是很重要了。在beta cell这块,先是anti-GAD 和-Insulin, 等T cell杀红眼了,
啥antigen都可以recognize。
--------------------------------------------------------------------
再上点干货:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580128/
Antigen-Based Therapy with Glutamic Acid Decarboxylase (GAD) Vaccine in
Patients with Recent-Onset Type 1 Diabetes: A Randomised Double-Masked
Controlled Trial
Findings
The ratio (experimental to control) of the adjusted population mean of C-
peptide for the GAD-alum ×3 and GAD-alum ×2/alum ×1 groups is 0.998 (95%
CI: [0.779, 1.22], p = 0.98) and 0.926 (95% CI: [0.720, 1.13], p = 0.50),
respectively. HbA1c and insulin use did not differ between groups. There was
no difference in rate or severity of adverse events between groups.
Interpretation $$$
Antigen-based immunotherapy therapy using GAD-alum given subcutaneously in
two or three doses over 4 to 12 weeks does not alter the course of loss of
insulin secretion over one year in subjects with recently diagnosed T1DM.
While antigen-based therapy is a highly desireable treatment and is
effective in animal models, translation to human autoimmune disease remains
a challenge.
相关阅读
吐槽一下搞生物的人:看看人家搞物理的,引力波这样艰苦卓绝,paper helpBioinformatics Specialist at USC, Los Angeles, Californiapaper help!paper help用CRISPR建stable cell linecomputational biology and systems biology 有审稿机会[转]第四届基因组与作物遗传改良国际会议特邀报告邀请函深深体会做PI的难处了 (转载)PNASpending final recom over 2 weekslentivirus 转染问题求助biostatisitcs 国内硕士能转 bioinformatics 吗paper help! (转载)Postdoc Position in Immunology请教大家关于Science Translational Medicine 的一些情况paper help please, fabaozi thanks!求paper,谢谢谢谢!!!!!!是dual PI 好, 还是co-investigator好?中医落后于西医的最大瓶颈在于没有可用的 模型onsite 面试,大家遇到过哪些challenging问题?